Open Access Open Access  Restricted Access Subscription or Fee Access

The Biogenesis, Transmission, Structural and Therapeutics on SARS-CoV-2 (COVID-19) Pandemic: Challenges and Global Perspective

Priyanka Bajpai, Om Prakash, Rohit Mohan, Amresh Gupta

Abstract


The present pandemic situation due to the appearance of COVID-19 has put the world in a miserable condition. About 2.5 million people have been infected with the strain of coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) globally. The foremost patient of COVID-19 infection was identified in China in the month of December 2019. Researchers are searching for an effective method to combat this pandemic virus. The investigations have been regulated by the scientists towards finding effective medicine, vaccine as well as robust techniques to detect and combat this virus. Furthermore, the evolution of new treatments, the application of clinical data analytics has also been observed for the off-label use of the already available approved medications. As a real-time application of science and technology, numerous clinical trials have been under process to find out the best medicine against the COVID-19 pandemic. The present study summarizes in the form of a comprehensive review conscripting the available knowledge about identification, genomic structure, and mode of infection, and clinical importance of SARS-CoV-2. Currently, available approaches for the detection of COVID-19 have been highlighted along with available treatments which have been explored by researchers worldwide includes precisely convalescent plasma therapy, monoclonal antibody therapy as well as antiviral agents from natural and synthetic sources, and regulatory status have been discussed elaborately which will enrich the global understanding as well as proficient ability to combat this pandemic pathogen


Keywords


COVID-19, SARS-CoV-2, SARS-CoV, MERS-CoV, Genomic architecture, Pathogenesis, Transmission, Therapy.

Full Text:

PDF

References


F Wu, S Zhao, B Yu, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798): 265–269.

S Su, G Wong, W Shi, et al. Epidemiology, genetic recombination, and pathogenesis of Coronaviruses. Trends Microbiol. 2016; 24(6): 490–502.

Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009; 7(6): 439–450.

Y Yin, RG Wunderink. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018; 23(2): 130–137.

R Lu, X Zhao, J Li, P Niu, B Yang, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224): 565–574.

JF-W Chan, K-H Kok, Z Zhu, H Chu, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 2020; 9(1): 221–236.

D Paraskevis, EG Kostaki, G Magiorkinis, et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol. 2020; 79: 104212.

Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270–273.

C Wu, Y Liu, Y Yang, P Zhang, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B. 2020; 10(5): 766–788.

C Drosten, S Günther, W Preiser, et al. Identification of novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003; 348(20): 1967–1976.

J Cui, F Li, ZL Shi. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019; 17(3): 181–192.

F Li. Structure, function and evolution of coronavirus spike protein. Annu. Rev. Virol. 2016; 3(1): 237–261.

Z Zhu, Z Zhang, W Chen, et al. Predicting the receptor-binding domain usage of the coronavirus based on kmer frequency on spike protein. Infect. Genet. Evol. 2018; 61: 183–184.

W Li, MJ Moore, N Vasilieva, et al. Angiotensin, converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965): 450–454.

Y Zhao, Z Zhao, Y Wang, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Bio Rxiv. 2020. doi: https://doi.org/10.1101/2020.01.26.919985.

A Wu, Y Peng, B Huang, X Ding, et al. Genome composition and divergence of the novel coronavirus (2019-nCov) originating in China. Cell Host Microbe. 2020; 27(3): 325–328.

WHO. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 December 2020. https://www.who.int/dg/speeches/detail/who-director-generalsremarks-at-the-media-brief

ing-on-2019-ncov-on-11-December-2020.

C Huang, Y Wang, X Li, L Ren, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.

R Wang, X Zhang, DM Irwin, Y Shen. Emergence of SARS-like coronavirus poses new challenge in China. J. Infect. 2020; 80(3): 350–371.

F Yu, R Jia, Y Tang, J Liu, B Wei. SARS-CoV-2 infection and stem cells: interaction and intervention. Stem Cell Res. 2020; 46: 101859.

JP Guo, M Petric, W Campbell, PL McGeer. SARS corona virus peptide recognized by antibodies in the sera of convalescent cases. Virology. 2004; 324(2): 251–256.

X Tang, C Wu, X Li, Y Song, X Yao, et al. On the origin and continuing evolution of SARS-Cov2. Natl. Sci. Rev. 2020; 7(6): 1012–1023.

E de Wit, N van Doremalen, D Falzarano, VJ Munster. SARS and MERS: recent insight into emerging coronaviruses. Nat. Rev. Microbiol. 2016; 14(8): 523–534.

PS Masters. The molecular biology of coronavirus. Adv. Virus Res. 2006; 66: 193–292.

MA Tortorici, D Veesler. Structural insights into coronavirus entry. Adv. Virus Res. 2019; 105: 93–116.

G Simmons, JD Reeves, AJ Rennekamp, et al. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U.S.A. 2004; 101(12): 4240–4245.

S Belouzard, VC Chu, GR Whittaker. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. U.S.A. 2009; 106(14): 5871–5876.

H Wang, P Yang, K Liu, F Guo, Y Zhang, G Zhang, C Jiang. SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway. Cell Res. 2008; 18(2): 290–301.

K Kuba, Y Imai, T Ohto-Nakanishi, JM Penninger. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol. Ther. 2010; 128(1): 119–128.

N Zhang, S Jiang, L Du. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines. 2014; 13(6): 761–774.

S Xia, Y Zhu, M Liu, Q Lan, W Xu, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell. Mol. Immunol. 2020; 17(7): 765–767.

F Yu, L Du, DM Ojcius, C Pan, S Jiang. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020; 22(2): 74–79.

AH De Wilde, EJ Snijder, M Kikkert, MJ van Hemert. Host factors in coronavirus replication. Curr. Top. Microbiol. Immunol. 2018; 419: 1–42.

SG Sawicki, DL Sawicki. Coronavirus transcription: a perspective. Curr. Top. Microbiol. Immunol. 2005; 287: 31–55.

J Ziebuhr, AE Gorbalenya, EJ Snijder. Virus-encoded proteinases and proteolytic processing in the Nidovirales J. Gen. Virol. 2000; 81(Pt 4): 853–879.

S Hussain, J Pan, Y Chen, Y Yang, J Xu, Y Peng, et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J. Virol. 2005; 79(9): 5288–5295.

A Perrier, A Bonnin, L Desmarets, A Danneels, et al. The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. J. Biol. Chem. 2019; 294(39): 14406–14421.

W Song, M Gui, X Wang, Y Xiang. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018; 14(8): e1007236.

J Shang, Y Wan, C Luo, G Ye, Q Geng, A Auerbach, F Li. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 2020; 117(21): 11727–11734.

G Simmons, DN Gosalia, AJ Rennekamp, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA. 2005; 102(33): 11876–11881.

Q Li, X Guan, P Wu, X Wang, L Zhou, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020; 382(13): 1199–1207.

I Hamming, W Timens, ML Bulthuis, et al. The emerging role of ACE2 in physiology and disease. J. Pathol. 2004; 212(1): 1–11.

D Wrapp, N Wang, KS Corbett, JA Goldsmith, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483): 1260–1263.

JSM Peiris, Y Guan, KY Yuen. Severe acute respiratory syndrome. Nat. Med. 2004; 10(12): S88–S97.

K Pyrc, B Berkhout, L van der Hoek. The novel human coronaviruses NL63 and HKU1. J Virol. 2007; 81(7): 3051–3057.

A Rahman, A Sarkar. Risk factors for fatal Middle East Respiratory Syndrome coronavirus infections in Saudi Arabia: analysis of the WHO line list, 2013–2018. Am. J. Public Health. 2019; 109(9): 1288–1293.

ZA Memish, AI Zumla, RF Al-Hakeem, AA Al-Rabeeah, GM Stephens. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 2013; 368(26): 2487–2494.

C Wang, PW Horby, FG Hayden, GF Gao. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223): 470–473.

M Giovanetti, D Benvenuto, S Angeletti, M Ciccozzi. The 2019-new coronavirus epidemic: evidence for virus evolution. J. Med. Virol. 2020; 92(4): 455–459.

T Hampton. Bats may be SARS reservoir. JAMA. 2005; 294(18): 2291.




DOI: https://doi.org/10.37591/rrjoi.v11i1.2383

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Research & Reviews: A Journal of Immunology